Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 19/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100363 | 0.87 | CXCR4 (0.46) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL5103796 | 0.85 | CXCR4 (0.40) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL30834051 | 0.83 | CXCR4 (0.52) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL4759592 | 0.83 | CXCR4 (0.52) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL5112746 | 0.83 | CXCR4 (0.52) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL5103871 | 0.83 | CXCR4 (0.52) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL2510499 | 0.82 | CXCR4 (0.50) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL7068507 | 0.78 | CXCR4 (0.53) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL5671385 | 0.78 | SLC40A1 (0.62) | CXCR4SLC40A1CHRM2CYP2D6DRD2 | |
| SCHEMBL6886947 | 0.78 | SLC40A1 (0.62) | CXCR4SLC40A1CHRM2CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885SLC40A1 2231/4885CHRM2 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.